The latest news, announcements and press releases from NorthX Biologics.
STOCKHOLM--(BUSINESS WIRE)-- NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity firm with deep expertise in pharmaceutical services. This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending U.S. commercial reach.
Amarna Therapeutics, a privately held biotechnology company specializing in transformative gene therapies, is pleased to announce its strategic collaboration with NorthX Biologics, a leading biologics manufacturing partner. This partnership represents a major step in advancing the clinical trial manufacturing of Nimvec™ AM510, Amarna’s groundbreaking gene therapy platform designed to transform the treatment of immune-mediated diseases. The collaboration will begin with the transfer of Amarna’s research-scale production process for Nimvec™ AM510 to NorthX Biologics. This critical step initiates the Chemistry, Manufacturing, and Controls (CMC) development process at NorthX, laying the groundwork for cGMP-compliant manufacturing to support First-in-Human (FiH) clinical trials. Together, the companies will focus on optimizing and scaling production processes to ensure high-quality, safe, and effective therapies for future clinical applications.
Neogap Therapeutics, a Swedish clinical-stage biotechnology company, has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy. Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials.
Neogap Therapeutics develops pTTL (personalised Tumour Trained Lymphocytes), a cell therapy designed to treat solid tumours by training the immune system to recognise and attack cancer cells through the patient’s unique neoantigens. Currently, pTTL is under evaluation in a Phase I/II clinical trial focused on assessing its safety and tolerability in patients with advanced colorectal cancer.
This is the News section of the company profile page for NorthX Biologics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
